Monoclonal Antibodies: Technology Maturation and New Strategies

Instructions

  • Read the following information before beginning the educational activity and click the "Continue" link at the bottom of the page.
  • View the educational activity.
  • Complete the CME post-test and evaluation.
  • After successful completion of the CME post-test and evaluation, you will receive the credit or participation certificate

*The CME post-test and evaluation must be completed by May 18, 2022 in order to receive the credit or participation certificate.

Target Audience

Physicians who wish to advance their current knowledge of Monoclonal Antibodies.

Learning Objectives

  1. Define mechanisms of action of antibody-based antitumor therapy
  2. Summarize therapeutic properties of, pharmacology of, and mechanisms of resistance to monoclonal antibody cancer treatment
  3. Describe links between antibody- and cell-based therapies

Accreditation and Credit Designation

The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The Society for Translational Oncology designates this CME activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

It is the policy of the Society for Translational Oncology (STO) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities through the disclosure of financial interests and other relationships.  As an education provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), STO must comply with the ACCME Standards for Integrity and Independence.

In accordance with the policy of STO, all persons in a position to control the content of a CME activity must disclose any financial relationships with ineligible companies occurring within the last 24 months. STO abides by a policy of anonymous peer review: disclosure of any financial relationships with ineligible companies/commercial interests will be reviewed by the CME Activity Directors with the ad hoc assistance of external reviewers; any conflicts of interest found will be mitigated prior to the activity.

Author Disclosure(s)

David R. Spriggs, MD

  • Consultant to Repertoire Immune Medicines (Cambridge MA)
  • Patents on anti MUC16 Antibodies – licensed to Eureka and Bristol Myers Squibb
  • Patents on Galectin 3 Neutralizing Antibodies

Moderator Disclosure

Bruce Chabner, M.D.

EMD Serono, Cyteir, Eli Lilly & Co., Boston Pharmaceuticals, Chugai Pharmaceuticals.

Aditya Bardia, M.D., MPH

Advisory role with Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Diiachi Pharma/Astra Zeneca, Puma Biotechnology, Biothernostics Inc., Phillips, Eli Lilly, Foundation Medicine.
Research funding from BGenentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Diiachi Pharma/Astra Zeneca. 


CME Activity Directors Disclosures

Jayne S. Gurtler, M.D., F.A.C.P.

No financial relationships relevant to the content of this activity have been disclosed.


Staff Planners Disclosures

No financial relationships relevant to the content of this actvity have been disclosed by the staff planners.


Commercial Support

This activity was funded in part through educational grants from Novartis Pharmaceuticals Corp. and Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.


Hardware/Software Requirements

The STO CME online supports the following browsers: current production versions of Safari, Firefox, Chrome and Explorer. Mobile devices with iOS and Android operating systems are also supported.

Other Links

Terms of Use Privacy Policy

Correspondence

Society for Translational Oncology
CME Online

318 Blackwell Street, Suite 270
Durham, North Carolina 27701
Phone: (919) 433-0489
Fax: (919) 680-4411
Email: CMEAdmin@sto-online.org